Pharma Business Hub / Pharmacy Business Update & News / Gym Business / Fitness Business / Pharmacy Trends / Pharmacy Technology / B2B pharmacy / Pharmacy Distributors
Latest Post
-
Is Starting a Semaglutide Clinic Profitable? Revenue Models Explained (2024 Guide)
read more >>: Is Starting a Semaglutide Clinic Profitable? Revenue Models Explained (2024 Guide)The Semaglutide Clinic Gold Rush: By the Numbers The obesity treatment market is exploding, with GLP-1 medications like semaglutide (Wegovy) driving $100B+ in annual revenue. For medical entrepreneurs, launching a semaglutide clinic can deliver 50-75% gross margins—but only with the right business model. This data-driven guide reveals: ✔ 5 proven revenue models with profit breakdowns✔…
-
From Theory to Action: How to Actually GDP Implement in Your Pharma Supply Chain
read more >>: From Theory to Action: How to Actually GDP Implement in Your Pharma Supply ChainGood Distribution Practice (GDP) compliance is non-negotiable in pharma—yet 47% of distributors fail inspections due to implementation gaps between policy and practice. This step-by-step playbook transforms GDP from a paper exercise into operational reality, covering:✔ A 90-day GDP implementation roadmap✔ Proven templates for SOPs, logs, and training✔ Tech tools that automate compliance✔ Real-world case studies…
-
The Legal Loophole? When Pharmacies CAN Distribute Without a License
read more >>: The Legal Loophole? When Pharmacies CAN Distribute Without a LicenseThe Surprising Exceptions to Pharmacy Licensing Rules In the highly regulated world of pharmaceutical distribution, most professionals assume that a valid pharmacy license is always required to dispense medications. However, there exist several perfectly legal exceptions that allow medication distribution without full pharmacy licensure under specific circumstances. This comprehensive guide examines the little-known regulatory loopholes,…
-
Novo Nordisk vs. Eli Lilly: The Battle for GLP-1 Supremacy
read more >>: Novo Nordisk vs. Eli Lilly: The Battle for GLP-1 SupremacyThe $100 Billion Weight Loss Drug War The pharmaceutical industry’s most intense rivalry is heating up as Novo Nordisk (semaglutide: Ozempic/Wegovy) and Eli Lilly (tirzepatide: Mounjaro/Zepbound) compete for dominance in the GLP-1 market, projected to exceed $100 billion by 2030. This analysis breaks down:✔ Revenue, market share, and growth trajectories✔ Pipeline advantages and R&D spending✔…
-
Branded vs. Compounded Semaglutide Risks, Costs, and Business Implications
read more >>: Branded vs. Compounded Semaglutide Risks, Costs, and Business ImplicationsThe Great Semaglutide Divide: Understanding Your Options The explosive demand for weight loss drugs has created two distinct markets: This analysis reveals:✔ 70% price differences between options✔ Hidden risks in compounded formulations✔ Why pharmacies and investors are racing to capitalize✔ The legal gray area fueling a $3B shadow market Cost Comparison: Breaking Down the Price…
-
Buy Semaglutide for Weight Loss: 2025’s Brutal New Rules for Legitimate Purchases
read more >>: Buy Semaglutide for Weight Loss: 2025’s Brutal New Rules for Legitimate PurchasesThe weight loss drug market has turned into a regulatory warzone. With counterfeit semaglutide now making up 22% of online sales, and Novo Nordisk restricting legitimate supply, patients face a dangerous landscape. Here’s what’s changed in 2025—and how to get buy semaglutide without getting scammed or arrested. The 3 Legal Ways to Get Semaglutide in…
-
SFDA 2025 New Rules: What Middle East Distributors Are Missing
read more >>: SFDA 2025 New Rules: What Middle East Distributors Are MissingThe Saudi Food and Drug Authority (SFDA) has introduced updated regulations for 2025, bringing significant changes for distributors and manufacturers in the Middle East. These rules impact product labeling, barcode compliance, and import requirements—yet many businesses remain unaware of critical updates, risking fines, shipment delays, and market access issues. This article breaks down the key…
-
Serialization 2025: New Deadlines Every Distributor Must Know
read more >>: Serialization 2025: New Deadlines Every Distributor Must KnowThe pharmaceutical and supply chain industries are entering a critical phase of serialization compliance. By 2025, new global regulations will take effect, requiring distributors to adopt stricter track-and-trace measures or face penalties. This guide covers the key 2025 deadlines, which products are affected, and actionable steps to ensure compliance. Why Serialization Deadlines Matter Serialization—assigning unique…
-
DSCSA Deadline Disaster? Why 60% of Distributors Aren’t Ready for Nov 2025
read more >>: DSCSA Deadline Disaster? Why 60% of Distributors Aren’t Ready for Nov 2025The Drug Supply Chain Security Act (DSCSA) enforcement deadline is November 27, 2025—but shockingly, 60% of pharmaceutical distributors risk non-compliance due to last-minute scrambles. This isn’t just about fines; it’s about business continuity. Companies that miss the deadline face:🔴 Shipment rejections at wholesalers🔴 Regulatory shutdowns for repeated violations🔴 Lost contracts with major pharmacy chains In…
